Navigation Links
Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
Date:6/19/2009

FRAZER, Pa., June 19 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced results from a pivotal clinical trial of lestaurtinib (CEP-701) in patients with relapsed acute myelogenous leukemia (AML) expressing FLT3 activating mutations. The study was designed to show the benefit of lestaurtinib in this patient population when given in sequence with standard induction chemotherapy compared to those treated with standard induction chemotherapy alone. An analysis of the study showed that patients who were treated with lestaurtinib showed similar rates of complete response but no increased benefit in overall survival, compared to those who received induction chemotherapy alone.

"We are disappointed that this study with lestaurtinib did not demonstrate a benefit for this patient population but we remain committed to oncology clinical research and developing innovative therapies for life-threatening diseases," said Dr. Lesley Russell, Executive Vice President and Chief Medical Officer at Cephalon.

The results of this study in relapsed AML will be submitted for presentation at a future medical meeting. The outcome of this study has no impact on the company's previously issued financial guidance for 2009.

"We made a significant financial investment in this pioneering effort to develop lestaurtinib for this molecularly targeted patient population with a poor prognosis and few treatment options," said Frank Baldino, Jr., Ph.D., Cephalon founder, chairman and CEO. "Patients with life-threatening diseases need companies like Cephalon to make that investment and take that risk if we are to improve patient outcomes and the overall cost of healthcare."

Developed by Cephalon scientists, lestaurtinib is a potent inhibitor of several tyrosine kinases including FLT3 and a Janu
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder
2. Cephalon Announces Positive Results From a Phase Two Study of NUVIGIL in Bipolar Depression
3. Cephalon Signs Option Agreement to Acquire Ception Therapeutics
4. Cephalon Receives Complete Response Letter Regarding Request for Expanded FENTORA Label for Non-Cancer Breakthrough Pain
5. Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkins Lymphoma
6. Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non-Hodgkins Lymphoma
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Celladon Provides MYDICAR(R) Program Update of First-In-Human Trial for Advanced Heart Failure at American Society of Gene Therapy Annual Meeting
9. Encorium Group Provides Update to LOI with Respect to the Sale of its U.S. Business
10. RAPAFLO(TM) (silodosin) Provides Rapid and Sustained Benign Prostatic Hyperplasia (BPH) Symptom Relief in as Little as Three Days
11. BioCryst Provides Peramivir Update and Reports First Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... Increasing unnecessary regulations on drug plans could inflict higher ... medications through a managed drug plan, according to a ... Analysis Senior Fellow Devon Herrick. "The ... helps makes medications affordable," says Herrick. "Blatant protectionism through ... protections, but more often than not they are designed ...
(Date:4/20/2015)... -- Stand Up To Cancer (SU2C) and the American Cancer ... Team to attack the number one cancer killer in America, ... American Association for Cancer Research (AACR), Scientific Partner to SU2C. ... the United States will be diagnosed with ... from it, making lung cancer the leading cause of cancer ...
(Date:4/20/2015)... Eli Lilly and Company (NYSE: LLY ... statistically superior to placebo in the treatment of patients ... proportion of patients achieving an ACR 20 response. ACR ... percent reduction in disease signs and symptoms as defined ... the 24-week, Phase 3 study, titled SPIRIT-P1, patients who ...
Breaking Medicine Technology:Restrictive Drug Plan Regulations Will Hurt Patients 2New SU2C-American Cancer Society Lung Cancer Dream Team Announced 2New SU2C-American Cancer Society Lung Cancer Dream Team Announced 3New SU2C-American Cancer Society Lung Cancer Dream Team Announced 4New SU2C-American Cancer Society Lung Cancer Dream Team Announced 5New SU2C-American Cancer Society Lung Cancer Dream Team Announced 6Lilly's Ixekizumab Met Primary Endpoint in a Phase 3 Study Investigating the Treatment of Psoriatic Arthritis 2Lilly's Ixekizumab Met Primary Endpoint in a Phase 3 Study Investigating the Treatment of Psoriatic Arthritis 3Lilly's Ixekizumab Met Primary Endpoint in a Phase 3 Study Investigating the Treatment of Psoriatic Arthritis 4
... Chilcott plc (Nasdaq: WCRX ) today announced a ... certain selling shareholders. The selling shareholders include funds ... Morgan Partners (advised by CCMP Capital) and Thomas H. ... of the Company,s senior management. The offering is ...
... Omeros Corporation (Nasdaq: OMER ), a biopharmaceutical company ... inflammation and disorders of the central nervous system, today ... Thursday, November 19, 2009 to discuss the Company,s third ... A. Demopulos, M.D., Chairman and CEO of Omeros, will ...
Cached Medicine Technology:Warner Chilcott Announces Secondary Equity Offering 2Warner Chilcott Announces Secondary Equity Offering 3Warner Chilcott Announces Secondary Equity Offering 4Omeros Corporation to Host Third Quarter 2009 Financial Results Conference Call on November 19 2
(Date:4/20/2015)... (PRWEB) April 20, 2015 Saint Joseph Regional ... 15 Top Health Systems by Truven Health Analytics, a leading ... quality of healthcare. SJRMC has been recognized by Truven Health ... the past four years. , According to Truven Health Analytics' ... Health Systems, in matchups with their peers, set the standard ...
(Date:4/20/2015)... 20, 2015 The American Association for ... and Safety Improvement as the 2015 winner of the ... association’s Annual Meeting, April 18, in Las Vegas, Nevada. ... team, patient safety can be dramatically improved,” said Peter ... CEO. “Northwestern Medicine and its Academy for Quality and ...
(Date:4/20/2015)... Rolling Meadows, IL (PRWEB) April 20, 2015 ... of Mutare Inc., has secured nationally-renowned Gastroenterologist Lawrence ... Medical Officer. , Dr. Kosinski brings a ... knowledge and vision to the Mutare Health ... solutions for improved communication, collaboration, and quality of ...
(Date:4/20/2015)... Lake City, Utah (PRWEB) April 20, 2015 ... End of Employer-Provided Health Insurance: Why It’s Good for ... 30, 2015. , Paul Zane Pilzer and Rick Lindquist ... of Employer-Provided Health Insurance: Why It’s Good for You ... to our nation’s employer health insurance woes - employer-funded ...
(Date:4/20/2015)... Advance Home Care Supply understands ... many customers would prefer not to share with others. As ... discreet delivery method allowing customers to order the products and ... without fear of a neighbor or passerby knowing what the ... now on all orders and no minimum order limit is ...
Breaking Medicine News(10 mins):Health News:SJRMC Named a 15 Top Health System by Truven Health Analytics 2Health News:SJRMC Named a 15 Top Health System by Truven Health Analytics 3Health News:2015 Leape Ahead Award honors Northwestern Medicine’s Academy for Quality and Safety Improvement 2Health News:2015 Leape Ahead Award honors Northwestern Medicine’s Academy for Quality and Safety Improvement 3Health News:Dr. Lawrence Kosinski Merges Medical, Technical, Business Expertise as CMO for Mutare Health 2Health News:Dr. Lawrence Kosinski Merges Medical, Technical, Business Expertise as CMO for Mutare Health 3Health News:Zane Benefits Announces Complimentary Book Giveaway On GoodReads: The End of Employer-Provided Health Insurance: Why It's Good for You and Your Company 2Health News:Zane Benefits Announces Complimentary Book Giveaway On GoodReads: The End of Employer-Provided Health Insurance: Why It's Good for You and Your Company 3Health News:Advance Home Care Supply Proud to Offer Discreet Delivery For All Orders 2Health News:Advance Home Care Supply Proud to Offer Discreet Delivery For All Orders 3
... the San Francisco Zoo had knowingly imported parakeets with a ... human interaction //. ,While the disease is not ... virus which causes psittacine beak and feather disease could pose ... bird's immune system causing abnormal feather growth and beak deformities. ...
... by scientists to clarify with the suspected case //. ... substance for testing it with the suspected virus in the ... it has been imported from Australia and stored in vials, ... suits are engaged to deal with the dangerous substance. ...
... is major problem in the quake affected areas of Indonesia. ... contact //with the bacteria Clostridium tetani. It is otherwise ... resulting in stiffness of the jaw. If not treated properly ... recent survey it has already killed 18 earthquake survivors in ...
... outbreak of malarial attack has made people to be feared and ... spread //. This non-endemic malarial attack has not been spread through ... mosquito (female anopheles) in Bahamas. ,In Exuma, a large ... to be known by the authorities later. The Haiti country is ...
... have warned of another outbreak of bird flu in Maharashtra ... culled// in the first episode of the dreaded virus outbreak ... bird flu in the Nandurbar and Jalgaon regions, giving a ... ,If experts of the technical committee set up by ...
... different dimension to eating disorder which seems to have ... during childhood and the formative years can lead to ... into an eating disorder in women, suggesting that the ... and separation anxiety. ,Dr. Alfonso Troisi and ...
Cached Medicine News:Health News:Experts Warn of Bird Flu Recurrence in Maharashtra 2
... The Strep B OIA test ... streptococcal antigen directly from cervical or ... If culture results are unknown at ... STREP B OIA offers physicians additional ...
... delivers excellent sensitivity and specificity for the diagnosis ... test that provides an answer in 6 minutes. ... provide improved patient care with a test that ... out what value we bring to your daily ...
... and nerve block procedures, Cadwells disposable ... a precisely machined Trocar (beveled) tip ... 61-cm (24-in) lead wire. Needle is ... use only. A starter kit includes ...
Shielding's new Surgical Drop Away / Flex Back Apron offers top of the shoulder velcro flaps for an adjustable fit. Features elastic back panels for added comfort and support. For quick removal apron...
Medicine Products: